ES2150418T3 - Composiciones farmaceuticas que comprenden calcitonina. - Google Patents

Composiciones farmaceuticas que comprenden calcitonina.

Info

Publication number
ES2150418T3
ES2150418T3 ES92303554T ES92303554T ES2150418T3 ES 2150418 T3 ES2150418 T3 ES 2150418T3 ES 92303554 T ES92303554 T ES 92303554T ES 92303554 T ES92303554 T ES 92303554T ES 2150418 T3 ES2150418 T3 ES 2150418T3
Authority
ES
Spain
Prior art keywords
pharmaceutical compositions
compositions including
including calcitonin
calcitonin
calcium deficiency
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92303554T
Other languages
English (en)
Inventor
Tudor Arvinte
Amelia Cudd
Judith Phillips
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of ES2150418T3 publication Critical patent/ES2150418T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

LA INVENCION PRESENTA CALCITONINA A MODO DE FIBRAS PARA UTILIZARLA EN EL TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON LA FALTA DE CALCIO.
ES92303554T 1991-04-23 1992-04-21 Composiciones farmaceuticas que comprenden calcitonina. Expired - Lifetime ES2150418T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919108634A GB9108634D0 (en) 1991-04-23 1991-04-23 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
ES2150418T3 true ES2150418T3 (es) 2000-12-01

Family

ID=10693744

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92303554T Expired - Lifetime ES2150418T3 (es) 1991-04-23 1992-04-21 Composiciones farmaceuticas que comprenden calcitonina.

Country Status (19)

Country Link
US (1) US5593962A (es)
EP (1) EP0510913B1 (es)
JP (1) JP3532580B2 (es)
KR (1) KR100245534B1 (es)
AT (1) ATE194775T1 (es)
AU (1) AU653395B2 (es)
CA (1) CA2066532C (es)
CY (1) CY2246B1 (es)
DE (1) DE69231263T2 (es)
DK (1) DK0510913T3 (es)
ES (1) ES2150418T3 (es)
GB (1) GB9108634D0 (es)
GR (1) GR3034414T3 (es)
IE (1) IE921278A1 (es)
IL (1) IL101622A (es)
MX (1) MX9201825A (es)
NZ (1) NZ242440A (es)
PT (1) PT510913E (es)
ZA (1) ZA922899B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595760A (en) * 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
AU3556400A (en) * 1999-03-17 2000-10-04 Novartis Ag Pharmaceutical compositions
EP1251867A4 (en) 2000-02-04 2004-12-08 Unigene Lab Inc NASAL CALCITON INFORMATION
AU2003287950B2 (en) * 2002-09-27 2009-01-29 Zentaris Gmbh Administration form for pharmaceutically active peptides with sustained release and method for the production thereof
GB0422644D0 (en) * 2004-10-12 2004-11-10 Novartis Ag Organic compounds
GB0511269D0 (en) 2005-06-02 2005-07-13 Creative Peptides Sweden Ab Sustained release preparation of pro-insulin C-peptide
CA2720864C (en) 2008-04-07 2017-07-04 National Institute Of Immunology Compositions useful for the treatment of diabetes and other chronic disorder

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61267528A (ja) * 1984-11-26 1986-11-27 Yamanouchi Pharmaceut Co Ltd 吸収促進剤を含有するカルシトニン経鼻剤
MY102411A (en) * 1986-12-23 1992-06-17 Ciba Geigy Ag Nasal solutions

Also Published As

Publication number Publication date
CY2246B1 (en) 2003-07-04
AU1506692A (en) 1992-10-29
KR100245534B1 (ko) 2000-03-02
DK0510913T3 (da) 2000-10-16
JP3532580B2 (ja) 2004-05-31
IL101622A (en) 1996-06-18
AU653395B2 (en) 1994-09-29
PT510913E (pt) 2000-12-29
DE69231263D1 (de) 2000-08-24
CA2066532A1 (en) 1992-10-24
EP0510913A2 (en) 1992-10-28
CA2066532C (en) 2003-08-19
IL101622A0 (en) 1992-12-30
US5593962A (en) 1997-01-14
ZA922899B (en) 1993-10-22
GB9108634D0 (en) 1991-06-12
ATE194775T1 (de) 2000-08-15
GR3034414T3 (en) 2000-12-29
DE69231263T2 (de) 2000-12-21
IE921278A1 (en) 1992-11-04
EP0510913A3 (en) 1993-12-15
JPH05139993A (ja) 1993-06-08
MX9201825A (es) 1992-10-01
NZ242440A (en) 1993-10-26
EP0510913B1 (en) 2000-07-19

Similar Documents

Publication Publication Date Title
MX9204229A (es) Trifluorometilbencilfosfonatos utiles en el tratamiento de osteoporosis.
UA26213C2 (uk) Засіб для профілактики та лікуваhhя остеопорозу та фармацевтичhа композиція hа їх осhові
DE69019363D1 (de) Desinfizierende zusammensetzung und desinfektionsverfahren.
DE69010162D1 (de) Zusammensetzung zur Behandlung von Entzündung.
FI972308A0 (fi) 2-substituoituja 1,2,5-tiadiatsolidin-3-oni-1,1-dioksideja ja niitä sisältäviä koostumuksia ja menetelmiä niiden käyttämiseksi
PT627221E (pt) Substancias antagonistas p para o tratamento de emese
PT88275A (pt) Processo para a preparacao de composicoes farmaceuticas contendo 5-amino ou amino substituido-1,2,3-triazois uteis como agentes antiproliferativos
SE9802937D0 (sv) Novel compounds
DK376188A (da) Farmaceutisk dosisenhed
ATE184913T1 (de) Mutanten von humanem antithrombin iii
ES2150418T3 (es) Composiciones farmaceuticas que comprenden calcitonina.
ES2177024T3 (es) Empleo de la fanquinoma para el tratamiento de la enfermedaad de alzheimer.
DE69010294D1 (de) Verwendung von Antiprogestomimetika zur Stimulierung des Eisprungs.
DE69626987D1 (de) Pharmaceutische komposition
MX9202507A (es) Composicion farmaceutica para el tratamiento de esofagitis de reflujo.
PT661058E (pt) Utilizacao de antagonistas da bradiquinina para o tratamento de doencas virais
MX9302142A (es) Uso de 3r- y 3r,s-difenilmetoxi-1-(3,4-metileno-dioxifenetil)-piperidina y composicion que la contienen.
DK0495226T3 (da) Anvendelse af 3-aryl-5-alkylthio-4H-1,2,4-triazoler til behandling af hyperrefleksi som følge af spinaltrauma
YU40098A (sh) Upotreba olanzapina za dobijanje leka
MX9203784A (es) Composiciones para el tratamiento de osteoporosis en seres humanos.
DE68905343T2 (de) Dosisform zur verabreichung von calciumantagonisten.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 510913

Country of ref document: ES